🇺🇸 FDA
Pipeline program

Orodispersible tablet, BUL03, Jorveza 1 mg orodispersible tablets

BUL-8/EEA

Phase 3 small_molecule active

Quick answer

Orodispersible tablet, BUL03, Jorveza 1 mg orodispersible tablets for eosinophilic esophagitis is a Phase 3 program (small_molecule) at Dr. Falk Pharma GmbH with 1 ClinicalTrials.gov record(s).

Program details

Company
Dr. Falk Pharma GmbH
Indication
eosinophilic esophagitis
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials